Artivion (AORT) Competitors

$22.24 -0.87 (-3.74%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$22.63 +0.40 (+1.78%)

As of 04:12 AM Eastern

AORT vs. BLCO, STVN, NVST, IRTC, and TMDX

Should you buy Artivion stock or one of its competitors? MarketBeat compares Artivion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artivion include Bausch + Lomb (BLCO), Stevanato Group (STVN), Envista (NVST), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.

How does Artivion compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Artivion (NYSE:AORT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Artivion had 20 more articles in the media than Bausch + Lomb. MarketBeat recorded 23 mentions for Artivion and 3 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.18 beat Artivion's score of 0.14 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Artivion	2 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artivion has a net margin of 2.55% compared to Bausch + Lomb's net margin of -4.21%. Artivion's return on equity of 7.15% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Artivion	2.55%	7.15%	3.63%

Artivion has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A
Artivion	$441.33M	2.45	$9.77M	$0.24	92.65

Bausch + Lomb has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Artivion has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Bausch + Lomb presently has a consensus price target of $18.08, indicating a potential upside of 11.45%. Artivion has a consensus price target of $47.83, indicating a potential upside of 115.13%. Given Artivion's stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Artivion beats Bausch + Lomb on 14 of the 16 factors compared between the two stocks.

How does Artivion compare to Stevanato Group?

Artivion (NYSE:AORT) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Artivion presently has a consensus price target of $47.83, indicating a potential upside of 115.13%. Given Artivion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Artivion is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Artivion had 11 more articles in the media than Stevanato Group. MarketBeat recorded 23 mentions for Artivion and 12 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.15 beat Artivion's score of 0.14 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	2 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Artivion has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Stevanato Group has a net margin of 11.76% compared to Artivion's net margin of 2.55%. Stevanato Group's return on equity of 10.27% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
Stevanato Group	11.76%	10.27%	6.08%

Stevanato Group has higher revenue and earnings than Artivion. Stevanato Group is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.45	$9.77M	$0.24	92.65
Stevanato Group	€1.34B	3.97	€158.21M	€0.59	29.81

Summary

Artivion and Stevanato Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Artivion compare to Envista?

Artivion (NYSE:AORT) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Artivion presently has a consensus price target of $47.83, indicating a potential upside of 115.13%. Envista has a consensus price target of $28.83, indicating a potential upside of 20.47%. Given Artivion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Artivion is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Artivion had 6 more articles in the media than Envista. MarketBeat recorded 23 mentions for Artivion and 17 mentions for Envista. Envista's average media sentiment score of 0.62 beat Artivion's score of 0.14 indicating that Envista is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	2 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Envista	4 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Envista has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.0% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Artivion has a net margin of 2.55% compared to Envista's net margin of 2.41%. Artivion's return on equity of 7.15% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
Envista	2.41%	7.11%	3.91%

Envista has higher revenue and earnings than Artivion. Envista is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.45	$9.77M	$0.24	92.65
Envista	$2.72B	1.43	$47M	$0.41	58.38

Summary

Artivion beats Envista on 11 of the 16 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

Artivion (NYSE:AORT) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

86.4% of Artivion shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Artivion had 18 more articles in the media than iRhythm Technologies. MarketBeat recorded 23 mentions for Artivion and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.81 beat Artivion's score of 0.14 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	2 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Artivion currently has a consensus price target of $47.83, indicating a potential upside of 115.13%. iRhythm Technologies has a consensus price target of $193.38, indicating a potential upside of 68.66%. Given Artivion's higher possible upside, analysts clearly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Artivion has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.45	$9.77M	$0.24	92.65
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A

Artivion has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Artivion has a net margin of 2.55% compared to iRhythm Technologies' net margin of -3.53%. Artivion's return on equity of 7.15% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

Summary

Artivion beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does Artivion compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Artivion (NYSE:AORT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Artivion had 9 more articles in the media than TransMedics Group. MarketBeat recorded 23 mentions for Artivion and 14 mentions for TransMedics Group. Artivion's average media sentiment score of 0.14 beat TransMedics Group's score of -0.23 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	2 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group currently has a consensus price target of $135.00, indicating a potential upside of 110.35%. Artivion has a consensus price target of $47.83, indicating a potential upside of 115.13%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

TransMedics Group has higher revenue and earnings than Artivion. TransMedics Group is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	3.66	$190.29M	$4.40	14.59
Artivion	$441.33M	2.45	$9.77M	$0.24	92.65

TransMedics Group has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market. Comparatively, Artivion has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

TransMedics Group has a net margin of 27.04% compared to Artivion's net margin of 2.55%. TransMedics Group's return on equity of 22.38% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Artivion	2.55%	7.15%	3.63%

Summary

TransMedics Group beats Artivion on 10 of the 16 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.12B	$6.90B	$6.30B	$22.96B
Dividend Yield	N/A	1.72%	2.79%	4.07%
P/E Ratio	92.65	49.93	20.99	28.29
Price / Sales	2.45	39.66	555.98	24.55
Price / Cash	20.97	24.21	42.94	25.11
Price / Book	2.40	6.49	9.70	4.73
Net Income	$9.77M	$158.34M	$3.55B	$1.07B
7 Day Performance	-37.16%	-1.83%	-0.56%	-1.11%
1 Month Performance	-41.39%	-1.10%	1.17%	1.36%
1 Year Performance	-23.12%	-2.35%	41.20%	24.41%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	4.2309 of 5 stars	$22.24 -3.7%	$47.83 +115.1%	-23.1%	$1.12B	$441.33M	92.65	1,800
BLCO Bausch + Lomb	4.4145 of 5 stars	$16.31 0.0%	$18.08 +10.9%	+36.8%	$5.81B	$5.10B	N/A	13,000
STVN Stevanato Group	2.9741 of 5 stars	€17.91 +0.7%	N/A	-28.0%	€5.43B	€1.34B	30.89	6,010	Earnings Report
NVST Envista	3.4368 of 5 stars	$25.82 -2.0%	$28.25 +9.4%	+28.0%	$4.29B	$2.72B	92.20	12,000	Analyst Downgrade
IRTC iRhythm Technologies	4.4204 of 5 stars	$119.18 -1.3%	$193.38 +62.3%	-18.0%	$3.97B	$747.14M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors

AORT vs. BLCO, STVN, NVST, IRTC, and TMDX

How does Artivion compare to Bausch + Lomb?

Summary

How does Artivion compare to Stevanato Group?

Summary

How does Artivion compare to Envista?

Summary

How does Artivion compare to iRhythm Technologies?

Summary

How does Artivion compare to TransMedics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artivion (AORT) Competitors

AORT vs. BLCO, STVN, NVST, IRTC, and TMDX

How does Artivion compare to Bausch + Lomb?

Do insiders & institutionals believe in BLCO or AORT?

Does the media favor BLCO or AORT?

Is BLCO or AORT more profitable?

Which has higher valuation & earnings, BLCO or AORT?

Which has more risk and volatility, BLCO or AORT?

Do analysts recommend BLCO or AORT?

Summary

How does Artivion compare to Stevanato Group?

Do analysts prefer AORT or STVN?

Does the media favor AORT or STVN?

Do insiders & institutionals believe in AORT or STVN?

Which has more volatility & risk, AORT or STVN?

Is AORT or STVN more profitable?

Which has stronger earnings & valuation, AORT or STVN?

Summary

How does Artivion compare to Envista?

Do analysts prefer AORT or NVST?

Does the media favor AORT or NVST?

Which has more volatility & risk, AORT or NVST?

Do insiders & institutionals believe in AORT or NVST?

Is AORT or NVST more profitable?

Which has stronger earnings & valuation, AORT or NVST?

Summary

How does Artivion compare to iRhythm Technologies?

Do institutionals & insiders believe in AORT or IRTC?

Does the media refer more to AORT or IRTC?

Do analysts prefer AORT or IRTC?

Which has higher earnings and valuation, AORT or IRTC?

Which has more risk & volatility, AORT or IRTC?

Is AORT or IRTC more profitable?

Summary

How does Artivion compare to TransMedics Group?

Do insiders and institutionals have more ownership in TMDX or AORT?

Does the media prefer TMDX or AORT?

Do analysts recommend TMDX or AORT?

Which has better valuation and earnings, TMDX or AORT?

Which has more risk & volatility, TMDX or AORT?

Is TMDX or AORT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools